Oxford University Hospitals NHS Foundation Trust



Myeloproliferative Neoplasm (MPN) / Polycythaemia Vera (PV) Clinical Trials Portfolio



NHS National Institute for Health Research Clinical Research Network

Recruiting PV Trials

KRT-232-102 (Interventional) Polycythaemia Vera PI: Prof Adam Mead	A Two-Part, Randomized, Open-label, Multicenter, Phase 2a/2b Study of the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared to Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemia Vera ***Eligibility Criteria:*** Age 18 or over, Diagnosis of PV, Phlebotomy dependent Part A: either Splenomegaly ≥ 450 cm^3 or absence of splenomegaly by CT/MRI; Part B: Splenomegaly by CT/MRI, Prior treatment with hydroxyurea (Part A and B) or interferon (Part A only) with resistance/intolerance to HU or IFN, ECOG performance status ≤ 2
TAMARIN (Interventional) All MPN PI: Prof Adam Mead	Effects of TAMoxifen on the Mutant Allele Burden and Disease Course in Patients with MyeloprolifeRatIve Neoplasms ***Eligibility Criteria:*** PV,ET,MF, Stable disease on hydroxyurea, interferon or ruxolitinib, No prior thrombosis, Age over 60, men aged between 50-59 may be considered, women must be post-menopausal
PHAZAR (Interventional) Accelerated or blast phase MPN PI: Prof Adam Mead	A Phase 1b Study to assess the safety and tolerability of oral Ruxolitinib in combination with Azacytidine in patients with Advanced Phase MPN, including MDS or AML arising from MPN ***Eligibility Criteria:*** Age 16 and over, Diagnosis of ET,PV or MF with > 10% bone marrow blasts (with or without dysplastic changes), ECOG performance status ≤ 3

MEASURES (Non-interventional) All MPN PI: Prof Adam Mead	The MPN Experimental Assessment of Symptoms by Utilizing Repetitive Evaluation (MEASURES) Trial: Serial Assessment of Symptomatic Response to Non Experimental Medical Therapies and/or Phlebotomy in Patients with Myeloproliferative Neoplasms ***Eligibility Criteria:*** All Ph- MPN patients starting a new, therapeutic intervention
INForMeD (Non-interventional) All MPN PI: Prof Adam Mead	An observational and biological research study to investigate the genetic and cellular basis of sporadic and familial myeloid disorders ***Eligibility Criteria:*** Age 2 or over, Patients under investigation for or diagnosed with a myeloid or related disorder, Patient willing to give consent to the study

Haematology Research contact details

Prof Adam Mead	Email: adam.mead@imm.ox.ac.uk Tel: 01865 222324
Research Nurse Team	Email: LP.haematology.RN@oxnet.nhs.uk

Last updated: March 2019